Safety and Immunogenicity Study of Ad26-ENVA and Ad35-ENV HIV Vaccines in Healthy HIV-uninfected Adults
NCT ID: NCT01215149
Last Updated: 2012-12-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
218 participants
INTERVENTIONAL
2010-10-31
2012-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Volunteers will be screened up to 56 days before vaccination and will be followed for 12 months after the second vaccination.
Approximately 212 volunteers will be randomized to receive either vaccine or placebo within a group (A-L); Groups A-D, Groups E-H and Groups I-L will be randomized separately. Up to 7% over-enrolment (approximately 15 volunteers) will be allowed to facilitate enrolment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A
Ad26.ENVA.01 at Month 0 followed by Ad35-ENV at Month 6. Vaccine:Placebo=10:3
Ad35-ENV vaccine
Recombinant adenovirus serotype 35 vector vaccine 5x10\^10 vp, delivered IM
Ad26.ENVA.01 vaccine
Recombinant adenovirus serotype 26 vector vaccine, 5x10\^10 vp delivered IM
Placebo Control
Colorless 10mm Tris/HCl buffer
Group B
Ad35-ENVA at Month 0 followed by Ad26.ENVA.01 at Month 6. Vaccine:Placebo=10:3
Ad35-ENV vaccine
Recombinant adenovirus serotype 35 vector vaccine 5x10\^10 vp, delivered IM
Ad26.ENVA.01 vaccine
Recombinant adenovirus serotype 26 vector vaccine, 5x10\^10 vp delivered IM
Placebo Control
Colorless 10mm Tris/HCl buffer
Group C
Ad26.ENVA.01 at Month 0 followed by Ad35-ENV at Month 3. Vaccine:Placebo=10:3
Ad35-ENV vaccine
Recombinant adenovirus serotype 35 vector vaccine 5x10\^10 vp, delivered IM
Ad26.ENVA.01 vaccine
Recombinant adenovirus serotype 26 vector vaccine, 5x10\^10 vp delivered IM
Placebo Control
Colorless 10mm Tris/HCl buffer
Group D
Ad35-ENV at Month 0 followed by Ad26.ENVA.01 at Month 3. Vaccine:Placebo=10:3
Ad35-ENV vaccine
Recombinant adenovirus serotype 35 vector vaccine 5x10\^10 vp, delivered IM
Ad26.ENVA.01 vaccine
Recombinant adenovirus serotype 26 vector vaccine, 5x10\^10 vp delivered IM
Placebo Control
Colorless 10mm Tris/HCl buffer
Group E
Ad26.ENVA.01 at Month 0 followed by Ad35-ENV at Month 3. Vaccine:Placebo=16:4
Ad35-ENV vaccine
Recombinant adenovirus serotype 35 vector vaccine 5x10\^10 vp, delivered IM
Ad26.ENVA.01 vaccine
Recombinant adenovirus serotype 26 vector vaccine, 5x10\^10 vp delivered IM
Placebo Control
Colorless 10mm Tris/HCl buffer
Group F
Ad35-ENV at Month 0 followed by Ad26.ENVA.01 at Month 3. Vaccine:Placebo=16:4
Ad35-ENV vaccine
Recombinant adenovirus serotype 35 vector vaccine 5x10\^10 vp, delivered IM
Ad26.ENVA.01 vaccine
Recombinant adenovirus serotype 26 vector vaccine, 5x10\^10 vp delivered IM
Placebo Control
Colorless 10mm Tris/HCl buffer
Group G
Ad26.ENVA.01 at Month 0 followed by Ad26.ENVA.01 at Month 3. Vaccine:Placebo=16:4
Ad26.ENVA.01 vaccine
Recombinant adenovirus serotype 26 vector vaccine, 5x10\^10 vp delivered IM
Placebo Control
Colorless 10mm Tris/HCl buffer
Group H
Ad35-ENV at Month 0 followed by Ad35-ENV at Month 3. Vaccine:Placebo=16:4
Ad35-ENV vaccine
Recombinant adenovirus serotype 35 vector vaccine 5x10\^10 vp, delivered IM
Placebo Control
Colorless 10mm Tris/HCl buffer
Group I
Ad26.ENVA.01 at Month 0 followed by Ad35-ENV at Month 3. Vaccine:Placebo=16:4
Ad35-ENV vaccine
Recombinant adenovirus serotype 35 vector vaccine 5x10\^10 vp, delivered IM
Ad26.ENVA.01 vaccine
Recombinant adenovirus serotype 26 vector vaccine, 5x10\^10 vp delivered IM
Placebo Control
Colorless 10mm Tris/HCl buffer
Group J
Ad35-ENV at Month 0 followed by Ad26.ENVA.01 at Month 3. Vaccine:Placebo=16:4
Ad35-ENV vaccine
Recombinant adenovirus serotype 35 vector vaccine 5x10\^10 vp, delivered IM
Ad26.ENVA.01 vaccine
Recombinant adenovirus serotype 26 vector vaccine, 5x10\^10 vp delivered IM
Placebo Control
Colorless 10mm Tris/HCl buffer
Group K
Ad26.ENVA.01 at Month 0 followed by Ad26.ENVA.01 at Month 3. Vaccine:Placebo=16:4
Ad26.ENVA.01 vaccine
Recombinant adenovirus serotype 26 vector vaccine, 5x10\^10 vp delivered IM
Placebo Control
Colorless 10mm Tris/HCl buffer
Group L
Ad35-ENV at Month 0 followed by Ad35-ENV at Month 3. Vaccine:Placebo=16:4
Ad35-ENV vaccine
Recombinant adenovirus serotype 35 vector vaccine 5x10\^10 vp, delivered IM
Placebo Control
Colorless 10mm Tris/HCl buffer
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ad35-ENV vaccine
Recombinant adenovirus serotype 35 vector vaccine 5x10\^10 vp, delivered IM
Ad26.ENVA.01 vaccine
Recombinant adenovirus serotype 26 vector vaccine, 5x10\^10 vp delivered IM
Placebo Control
Colorless 10mm Tris/HCl buffer
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least 18 years of age on the day of screening and has not reached his/her 51st birthday on the day of first vaccination;
* Willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study;
* In the opinion of the Principal Investigator or designee, and based on Assessment of Informed Consent Understanding (AOU) results, has understood the information provided and potential risks linked to vaccination and participation in the trial; written informed consent will be provided by the volunteer before any study-related procedures are performed;
* Willing to undergo HIV testing, risk reduction counselling, receive HIV test results and committed to maintaining low risk behaviour for the trial duration as defined by the protocol;
* If a female of childbearing potential, willing to use an effective non-barrier method of contraception (oral or injectable hormonal contraceptive; intrauterine device \[IUD\]) from screening until at least 4 months after the last study vaccination;
* Assessed by the clinic staff as being at "low risk" for HIV infection on the basis of sexual behaviours within the 12 months prior to enrolment;
* All female volunteers must be willing to undergo pregnancy tests at time points indicated in the protocol and must test negative prior to each study vaccination;
* All sexually active males (unless anatomically sterile) must be willing to use an effective method of contraception (such as consistent condom use) from the day of first vaccination until at least 4 months after the last vaccination;
* Willing to forgo donations of blood or any other tissues during the study and, for those who test HIV positive due to trial vaccination (vaccine-induced HIV seropositivity), until the anti-HIV antibody titers become undetectable.
Exclusion Criteria
* Any clinically relevant abnormality on history or examination including history of immunodeficiency or autoimmune disease; use of systemic corticosteroids (the use of topical or inhaled steroids is permitted); immunosuppressive, anticancer, antituberculosis or other medications considered significant by the investigator within the previous 6 months;
* Any clinically significant acute or chronic medical condition that is considered progressive, or in the opinion of the investigator, makes the volunteer unsuitable for participation in the study;
* Reported risky behaviour for HIV infection within 12 months prior to vaccination, as defined by the protocol
* If female, pregnant or planning a pregnancy within 4 months after last vaccination; or lactating;
* Asthma requiring high-dose oral or inhaled corticosteroids;
* Fever \> 100.4° F/38.0° C within 72 hours prior to vaccine administration;
* Bleeding disorder that was diagnosed by a physician (e.g., factor deficiency, coagulopathy or platelet disorder that requires special precautions) (Note: A volunteer who states that he or she has easy bruising or bleeding, but does not have a formal diagnosis and has IM injections and blood draws without any adverse experience is eligible);
* History of splenectomy;
* Any abnormal laboratory parameters as defined by the protocol;
* Receipt of live-attenuated vaccine within the previous 60 days or planned receipt within 60 days after vaccination with Investigational Product (within 14 days for live attenuated influenza vaccine \[LAIV\]); or receipt of other vaccine (e.g., influenza, pneumococcal), allergy treatment with antigen injections or tuberculin skin test within the previous 14 days or planned receipt within 14 days after vaccination with Investigational Product;
* Receipt of blood transfusion or blood-derived products within the previous 3 months;
* Participation in another clinical trial of an Investigational Product currently, within the previous 3 months or expected participation during this study;
* Receipt of another investigational HIV vaccine candidate (Note: receipt of an HIV vaccine control or placebo will not exclude a volunteer from participation if documentation is available and the Medical Monitor gives approval);
* History of severe local or systemic reactogenicity to vaccines (e.g., anaphylaxis, respiratory difficulty, angioedema);
* Confirmed diagnosis of active hepatitis B, hepatitis C or active syphilis;
* Seizure disorder: A participant who has had a seizure in the last 3 years is excluded. (Not excluded: a participant with a history of seizures who has neither required medications nor had a seizure for 3 years.);
* Psychiatric condition that precludes compliance with the protocol. Specifically excluded are persons with psychoses within the past 3 years, ongoing risk for suicide, or history of suicide attempt or gesture within the past 3 years.
18 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
HIV Vaccine Trials Network
NETWORK
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Beth Israel Deaconess Medical Center
OTHER
Ragon Institute of MGH, MIT and Harvard
OTHER
International AIDS Vaccine Initiative
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lindsey Baden, MD
Role: PRINCIPAL_INVESTIGATOR
Brigham and Women's Hospital, Boston, MA, USA
Gaudensia Mutua, MB ChB, MPH
Role: PRINCIPAL_INVESTIGATOR
Kenya AIDS Vaccine Initiative, Kangemi, Kenya
Etienne Karita, MD, M.Sc., MSPH
Role: PRINCIPAL_INVESTIGATOR
Projet San Francisco
Linda-Gail Bekker, MD
Role: PRINCIPAL_INVESTIGATOR
Desmond Tutu HIV Foundation-Emavundleni Research Center
Glenda Gray, MBBCH, FCPaeds(SA)
Role: PRINCIPAL_INVESTIGATOR
Perinatal HIV Research Unit
Liesl Page-Shipp
Role: PRINCIPAL_INVESTIGATOR
Aurum Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Brigham and Women's Hospital
Boston, Massachusetts, United States
Kenya AIDS Vaccine Initiative
Kangemi, , Kenya
Projet San Francisco
Kigali, , Rwanda
Desmond Tutu HIV Foundation-Emavundleni Research Centre
Cape Town (Nyanga), , South Africa
Aurum Institute
Klerksdorp, , South Africa
Perinatal HIV Research Unit
Soweto, , South Africa
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Baden LR, Karita E, Mutua G, Bekker LG, Gray G, Page-Shipp L, Walsh SR, Nyombayire J, Anzala O, Roux S, Laher F, Innes C, Seaman MS, Cohen YZ, Peter L, Frahm N, McElrath MJ, Hayes P, Swann E, Grunenberg N, Grazia-Pau M, Weijtens M, Sadoff J, Dally L, Lombardo A, Gilmour J, Cox J, Dolin R, Fast P, Barouch DH, Laufer DS; B003-IPCAVD004-HVTN091 Study Group. Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial. Ann Intern Med. 2016 Mar 1;164(5):313-22. doi: 10.7326/M15-0880. Epub 2016 Feb 2.
Related Links
Access external resources that provide additional context or updates about the study.
International AIDS Vaccine Initiative
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IAVI B003/ IPCAVD-004
Identifier Type: -
Identifier Source: org_study_id